Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01554618 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
NCT01554618 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 84 participants.
The verdict
NCT01554618, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
Study Summary
The study examines the Safety and efficacy study of exenatide once weekly in children and adolescents with type 2 diabetes
Interventions
- DRUG Placebo
- DRUG Exenatide Once Weekly
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2011-12-02 |
| Est. Completion | 2021-05-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01554618
The ClinicalTrials.gov registry entry for NCT01554618 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01554618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01554618 about?
NCT01554618 is a clinical study titled "Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes". The study examines the Safety and efficacy study of exenatide once weekly in children and adolescents with type 2 diabetes
What is the current status of trial NCT01554618?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2011-12-02. Estimated completion is 2021-05-05.
What interventions are being tested in trial NCT01554618?
The interventions under investigation include: Placebo (DRUG), Exenatide Once Weekly (DRUG).
Who is sponsoring clinical trial NCT01554618?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.